XML 43 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Segments (Tables)
3 Months Ended
Mar. 31, 2026
Segments  
Schedule of segment net loss (income) by significant expense category

The following table presents reportable segment net loss, including significant expense categories, attributable to the Company’s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):

Three Months Ended

March 31, 

2026

  ​ ​ ​

2025

  ​ ​ ​

Compensation and benefits, excluding stock-based compensation

$

3,027

$

2,239

Stock-based compensation

2,650

 

1,251

Drug manufacturing

431

 

1,830

Clinical trials

5,043

 

1,927

Outside general and administrative

1,244

 

946

Facilities and insurance

558

 

780

Other segment items (1)

1,924

 

949

Total segment expense

14,877

 

9,922

Non-operating income, net

(1,185)

 

(25,115)

Net loss

$

13,692

 

$

(15,193)

(1)Includes consulting, non-clinical research and laboratory supplies.